Abstract
Due to the high multidrug-resistant (MDR) and carbapenem-resistant (CR) rates for Pseudomonas aeruginosa and Acinetobacter baumannii, isolates obtained from respiratory tract infections (RTIs), intra-abdominal infections (IAIs), and urinary tract infections (UTIs) only maintained high susceptibility rates to colistin between 2015 and 2017.
Introduction
The rise of non-fermenting, Gram-negative "superbugs" is a critical global health crisis. In China, A. baumannii and P. aeruginosa are notorious for causing difficult-to-treat nosocomial infections in the lungs, abdomen, and urinary tract. The widespread use of broad-spectrum antibiotics has driven these bacteria to evolve sophisticated defense mechanisms, particularly against carbapenems, which were once the gold standard for treatment. This study quantifies the resistance landscape across China and evaluates the efficacy of colistin, an older antibiotic revived for its potency against MDR strains.
Methods
The study utilized data from the SMART (Study for Monitoring Antimicrobial Resistance Trends) program, collecting 3,246 isolates from 21 hospitals across seven geographical regions in China between 2015 and 2017. Minimum Inhibitory Concentrations (MICs) were determined using the broth microdilution method. Results were interpreted using the 2017 Clinical and Laboratory Standards Institute (CLSI) guidelines. MDR was defined as resistance to three or more of six key antibiotic classes, while CR (Carbapenem-Resistant) referred to resistance to either imipenem or meropenem.
Results and Discussion
The Resistance Crisis
Resistance levels in A. baumannii are staggering, with 80.1% of isolates identified as MDR and 78.7% as carbapenem-resistant. While P. aeruginosa showed lower rates (36.2% MDR and 38.9% CR), the prevalence remains a significant clinical concern. Resistance patterns varied by infection site; isolates from the urinary tract (UTIs) were significantly more susceptible to antibiotics than those from the lungs (RTIs) or abdomen (IAIs).
Colistin: The Last Bastion
Despite the high prevalence of MDR and CR strains, colistin susceptibility remained remarkably high and stable throughout the study period. Susceptibility to colistin was 95.7% for A. baumannii and 94.6% for P. aeruginosa.
As illustrated in Figure 1, the susceptibility of A. baumannii to other common drugs like amikacin (~33%), ciprofloxacin (~18%), and cefepime (~19%) was dismal compared to the near-universal efficacy of colistin. This stability suggests that while MDR/CR strains have become firmly established in the Chinese clinical environment, colistin remains a highly effective "last-line" defense.
Consistency Across Clinical Settings
Colistin's efficacy was not limited to specific regions or infection types but was consistent across various hospital departments.
Figure 2 demonstrates that colistin susceptibility remained constantly high (often near 100%) across critical care units (ICUs), emergency rooms, and surgical wards. This highlights its critical role in treating severe hospital-acquired infections where other treatments fail.
Conclusion
Between 2015 and 2017, resistance rates in China remained consistently high, indicating a stabilized MDR environment. While colistin currently holds the line, its recent approval for human clinical use in China necessitates aggressive monitoring to prevent the emergence of resistance. Future work must focus on molecular studies to identify the specific resistance genes, such as mcr-1, driving these trends.
Summary updated